Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation.

Autor: Beddok A; Department of Radiation Oncology, institut Godinot, Reims, France; Université de Reims Champagne-Ardenne, Crestic, Reims, France; Yale PET Center, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, USA. Electronic address: a.beddok@gmail.com., Orlhac F; Institut Curie, université PSL, université Paris Saclay, Inserm Lito U1288, Orsay, France., Rozenblum L; Yale PET Center, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, USA; Department of Nuclear Medicine, hôpitaux universitaires la Pitié Salpêtrière-Charles-Foix, AP-HP, Sorbonne université, 75013 Paris, France., Calugaru V; Institut Curie, université PSL, université Paris Saclay, Inserm Lito U1288, Orsay, France; Department of Radiation Oncology, institut Curie, université PSL, Paris, France., Créhange G; Institut Curie, université PSL, université Paris Saclay, Inserm Lito U1288, Orsay, France; Department of Radiation Oncology, institut Curie, université PSL, Paris, France., Dercle L; Department of Radiology, New York-Presbyterian Hospital, Columbia University, Vagelos College of Physicians and Surgeons, New York, USA., Nioche C; Institut Curie, université PSL, université Paris Saclay, Inserm Lito U1288, Orsay, France., Thariat J; Department of Radiation Oncology, centre François-Baclesse, Caen, France., Marin T; Yale PET Center, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, USA., El Fakhri G; Yale PET Center, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, USA., Buvat I; Institut Curie, université PSL, université Paris Saclay, Inserm Lito U1288, Orsay, France.
Jazyk: angličtina
Zdroj: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2024 Nov; Vol. 28 (6-7), pp. 597-602. Date of Electronic Publication: 2024 Oct 15.
DOI: 10.1016/j.canrad.2024.09.002
Abstrakt: Purpose: This review systematically investigates the role of radiomics in radiotherapy, with a particular emphasis on the use of quantitative imaging biomarkers for predicting clinical outcomes, assessing toxicity, and optimizing treatment planning. While the review encompasses various applications of radiomics in radiotherapy, it particularly highlights its potential for guiding reirradiation of recurrent cancers.
Methods: A systematic review was conducted based on a Medline search with the search engine PubMed using the keywords "radiomics or radiomic" and "radiotherapy or reirradiation". Out of 189 abstracts reviewed, 147 original articles were included in the analysis. These studies were categorized by tumor localization, imaging modality, study objectives, and performance metrics, with a particular emphasis on the inclusion of external validation and adherence to a standardized radiomics pipeline.
Results: The review identified 14 tumor localizations, with the majority of studies focusing on lung (33 studies), head and neck (27 studies), and brain (15 studies) cancers. CT was the most frequently employed imaging modality (77 studies) for radiomics, followed by MRI (46 studies) and PET (13 studies). The overall AUC across all studies, primarily focused on predicting the risk of recurrence (94 studies) or toxicity (41 studies), was 0.80 (SD=0.08). However, only 24 studies (16.3%) included external validation, with a slightly lower AUC compared to those without it. For studies using CT versus MRI or PET, both had a median AUC of 0.79, with IQRs of 0.73-0.86 for CT and 0.76-0.855 for MRI/PET, showing no significant differences in performance. Five studies involving reirradiation reported a median AUC of 0.81 (IQR: 0.73-0.825).
Conclusion: Radiomics demonstrates considerable potential in personalizing radiotherapy by improving treatment precision through better outcome prediction and treatment planning. However, its clinical adoption is hindered by the lack of external validation and variability in study designs. Future research should focus on implementing rigorous validation methods and standardizing imaging protocols to enhance the reliability and generalizability of radiomics in clinical radiotherapy, with particular attention to its application in reirradiation.
(Copyright © 2024 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: